
India scores high in graphic health warnings, cessation bans: WHO report on global tobacco use
Health warnings are an effective way to help people quit tobacco use and India is among the countries identified as having best-practice-level graphic health warning labels in 2024, showed a WHO report released on Monday.
The World Health Organisation's Global Tobacco Epidemic 2025 report, which focusses on measures to warn people about the harms of tobacco, revealed that the most striking gains have been in graphic health warnings, one of the key measures under the WHO Framework Convention on Tobacco Control (FCTC).
The report focuses on six proven WHO MPOWER tobacco control measures to reduce tobacco use, which claims over seven million lives a year.
A total of 110 countries now require these measures — up from just nine in 2007 — protecting 62 per cent of the global population; and 25 countries have adopted plain packaging. Currently, 110 countries with a total of five billion people are protected by strong graphic health warnings. This is an increase of 101 countries and 4.7 billion people since 2007.
Of all MPOWER measures, large graphic health warnings on cigarette packages have seen the most progress since 2007 – both in terms of the number of countries and population covered by a best-practice policy. Not only are more countries adopting graphic health warnings, but the average size of warnings has increased from 28 per cent in 2007 to almost 60 per cent in 2024.
Dr Vinayak Mohan Prasad, head of the Global Tobacco Control Programme, at the World Health Organisation's (WHO) headquarters in Geneva, told The Indian Express that India has achieved the highest status in O and W (both in 2016) and is in the second highest category of other measures, including M (mass media). 'Health warnings on cigarette packs are among the largest in the world at 85 per cent. Only 10 countries have a larger graphic health warning,' he said.
While WHO officials said daily adult smoking prevalence in India was seven per cent in 2023, they have not made estimates for smokeless tobacco use. According to Dr Prasad, the prevalence of current tobacco use among adults in the country is trending down and is on track to meet the 2025 Non-Communicable Disease (NCD) GAP target.
'However, prevalence is still higher than the global average. The largest population survey (National Family Health Survey 2021) shows 38 per cent of men and nine per cent of women are current users of tobacco while the global average in 2021 was 35 per cent among men and eight per cent among women,' said Dr Prasad.
He explained that smoking rates were lower than smokeless tobacco use among adults. Among children aged 13-15 (Global Youth Tobacco Survey-2019), eight per cent are using tobacco with little difference between boys and girls.
Where India stands
Meanwhile, India has banned smoking at all indoor public places, but still allows designated smoking rooms at restaurants/drinking facilities/nightclubs with a seating capacity of 30 or more as well as at airports and hotels.
On the ˋW' measure, India has been in the highest group since 2016. Large pictorial warnings (85 per cent) are required on tobacco product packages and India should also consider adopting plain packaging, said Dr Prasad.
On the 'E' measure, India has banned direct and indirect tobacco advertising, promotion and sponsorships. However, there is no ban on internet sales and India should completely ban advertising of tobacco products at points of sale, the expert urged. The WHO report also warned that action is needed to maintain and accelerate progress in tobacco control as rising industry interference challenges tobacco policies and control efforts.
At a press conference, Dr Ruediger Krech, Director of Health Promotion, WHO, said significant strides have been made in protecting people from the harms of tobacco.
'Today, over 6.1 billion people, three -quarters of the global population, are covered by at least one life saving policy. Brazil, Mauritius, The Netherlands and Turkey have implemented the full MPOWER package. Seven more, including Ireland , Ethiopia and Mexico, are just one step away,' said Dr Krech.
However, Dr Krech also cautioned about some of the warning signs as 134 countries have failed to make cigarettes less affordable and the spread of e-cigarettes and tobacco products are being aggressively marketed to youngsters. 'We are calling on governments to act boldly and raise taxes to best practice levels,' he urged.
Tobacco tax least adopted MPOWER measure in India
India has implemented stringent measures to curb tobacco advertising, promotion and sponsorship (TAPS) across all forms of media, including television, radio, print and digital platforms. To restrict depiction of tobacco use in entertainment media, the Centre introduced the Tobacco-Free Films and Television Rules in 2012, focusing on traditional platforms such as cinema and television.
As more people shift towards using digital streaming platforms, India recognized the need to update its tobacco control policies. Coinciding with World No Tobacco Day on May 31, 2023, the government introduced an amendment to the 2012 legislation, extending its coverage to over-the-top streaming platforms. With this move, India became the first country in the world to apply tobacco control regulations specifically to digital streaming content.
The WHO report said that India is reinforcing its commitment to public health and positioning itself as a pioneer in adapting regulation to evolving media consumption trends. However, the current national TAPS ban can be further strengthened by prohibiting tobacco advertising at points of sale and fully banning tobacco industry sponsorship.
Tobacco tax is the least-adopted MPOWER measure, despite raising tobacco prices continuing to be the most effective and efficient way to reduce tobacco use. In India, cigarettes are still affordable, as per the report. In 2024, only 15 per cent of the world's population living in 40 countries were protected by tax at 75 per cent or more of the price of the most popular brand of cigarette.
Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition.
... Read More
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
an hour ago
- Hindustan Times
Harnessing India's medical colleges in the fight against TB
India has made undeniable progress in its battle against tuberculosis (TB). The World Health Organization (WHO) acknowledged a 17.7% drop in TB incidence in the country from 237 to 195 per lakh population between 2015 and 2023 – double the pace observed globally. Despite these advancements, India continues to bear the highest TB burden globally1, making the goal of a TB-free India even more urgent. Against this backdrop, medical colleges have emerged as vital players in the national TB response - providing a template for other disease programmes to tap into their potential for a healthier India. TB (AFP) Harnessing India's vast network of medical colleges is a cornerstone of the nation's ambitious strategy to eliminate TB by 2025. These institutions have transitioned from peripheral actors to central pillars in the fight against TB, contributing significantly to nearly every facet of the National Tuberculosis Elimination Programme (NTEP). Medical colleges have evolved beyond tertiary referral centres to become critical nodes in India's public health infrastructure and the TB elimination response. They serve patients from both within and beyond their districts and states, offering significant potential for case detection not just in TB and respiratory departments, but across all specialties. Equipped with advanced laboratories and specialised centres, nearly all of India's 651 medical colleges are working closely with the NTEP. Notably, 336 medical colleges have centres dedicated to managing drug-resistant TB, a more complex and harder-to-treat form of the disease. With cutting-edge diagnostic tools and clinical expertise in handling health complications, these institutions are leading to better TB care and outcomes. In 2023, medical colleges notified nearly 14% of all TB cases in India – a clear sign of their growing role in this national effort. Medical colleges are playing an increasingly important role in responding to the emerging trends in the TB epidemic. Extra-pulmonary forms of the disease that occur outside the lungs are on the rise and are generally harder to detect and treat. It now makes up 20-24% of all TB cases in India, especially among people with weaker immunity. With their advanced labs, specialist departments, and tertiary care capacity, medical colleges are uniquely positioned to deliver the multi-disciplinary care required to detect and manage these harder-to-treat cases. Medical colleges are also well placed to design and implement innovative health solutions, with research and practice occurring side by side. For example, the Bharati Vidyapeeth Medical College in Pune repurposed its Family Adoption Programme – where each student engages with five families over three years – to integrate community-based TB screening into the existing medical curriculum. This not only helped detect cases in the community, but also taught students to recognise key TB symptoms, demonstrating a scalable model for active case finding. One of our standout achievements has been fostering global collaborations. The ongoing partnership between AIIMS Gorakhpur and Johns Hopkins University through the TB-Free Schools initiative aimed at early detection, treatment, and prevention of TB among students in residential schools, demonstrates how Indian medical colleges can drive impactful international engagement. As this model is scaled, it reinforces what we have long championed—that medical colleges, when systematically integrated with state health systems, are among the most cost-effective and scalable platforms for delivering high-impact TB interventions. By leveraging these institutions, we can enhance passive case finding, improve diagnosis, and ensure timely treatment. With a structured mechanism for accountability under NTEP, medical colleges can become hubs for TB management. Furthermore, they are instrumental in building a competent healthcare workforce by integrating practical, programme-oriented TB management skills into the medical curriculum, thereby preparing a new generation of doctors for the challenges of TB elimination. Through a structured framework of national, zonal, and state-level task forces, medical colleges contribute to operational research, generating vital evidence to refine public health strategies and improve patient outcomes. By embedding themselves within the community through initiatives like the Family Adoption Programme, they also bolster active case finding efforts, ensuring early diagnosis and treatment, thus playing an indispensable and multifaceted role in India's journey towards a TB-free future. For TB and other critical public health challenges, where understanding patient behavior, treatment barriers, and local epidemiology is critical, the ability of medical colleges to connect science with ground-level implementation is key to turning policy into real-world action. They have technical expertise to strengthen surveillance systems, research capacity to strengthen monitoring and evaluation, and educational mandate to build local capability through supportive supervision. The integration of medical colleges into the TB elimination framework has been one of the most strategic shifts under the NTEP. Medical colleges have redefined their role in public health, not only by contributing to TB management, but by setting a precedent for how academic institutions can anchor systemic change. Their success is not incidental; it is the result of sustained collaboration, institutional commitment, and a shared vision of making India TB-free. Importantly, the integration of medical colleges into the TB response offers a replicable framework for tackling other complex health challenges in India – such as anti-microbial resistance, non-communicable diseases, and neglected tropical diseases – through a blend of research, education, service delivery, and community engagement. This article is authored by Dr Ashok Bhardwaj, professor emeritus, MM Medical & Hospital College Solan, Himachal Pradesh and chairperson of the National Task Force for Medical Colleges under NTEP and Dr Bhupendra Tripathi, deputy director, Infectious Diseases and Vaccine Delivery, Gates Foundation, India.


Time of India
2 hours ago
- Time of India
AIIMS Bhopal detects dominance of new XFG Covid variant, finds no trace of Nimbus strain
Bhopal: AIIMS Bhopal is reporting 'no detection' of NB.1 ( Nimbus variant ) in their sequenced samples from Madhya Pradesh, despite its classification as a 'Variant Under Monitoring' by the WHO. AIIMS Bhopal's data shows the early dominance of XFG in MP, while NB.1.8.1 is more prominent in other regions like Delhi, Maharashtra, and Kerala. Regional Virology Laboratory at AIIMS Bhopal completed sequencing of 44 Covid-19 positive samples collected between May and June 2025. The samples originated from Bhopal (14), Gwalior (22), Tikamgarh (2), and Indore, Khargon, Chhindwara, Lalitpur, Sidhi, and Gaya (one each). Analysis showed XFG variant as the dominant strain, present in 28 of 44 samples (63.6%). This variant, which developed from the LF.7 variant, was initially identified in May 2025, increased through early June, and became exclusive by late June. XFG.3, a new sub-variant evolved from XFG lineage, appeared in 5 of the 28 XFG-positive samples. The LF.7 variant, which represented 50% of samples in May, gradually decreased until its complete absence by late June. Both XFG and LF.7 variants can affect vaccinated individuals but have only caused mild or asymptomatic infections. The WHO has not categorised them as 'Variants of Concern' or 'Variants Under Monitoring.' AIIMS Bhopal director Dr Ajai Singh said, "AIIMS Bhopal Regional Virology Laboratory is working with scientific rigor to ensure that no emerging viral variant goes undetected. The early detection of variants like XFG and its sub-lineages helps us understand the virus's behavior and take timely precautionary public health measures." Regular genomic sequencing serves as an essential component of epidemic preparedness and response. AIIMS Bhopal advocates for consistent genomic surveillance of SARS-CoV-2 as a crucial public health activity in Madhya Pradesh and adjacent regions. This surveillance strategy enables early detection, prompt intervention, and improved readiness against potential future Covid-19 outbreaks or emerging variants.


NDTV
4 hours ago
- NDTV
Scorpion Venom Could Be Used To Treat Breast Cancer
In a groundbreaking scientific development, Brazilian scientists have claimed that scorpion venom could help treat breast cancer. As per the study findings presented at FAPESP Week France, researchers at the University of Sao Paulo found a molecule in the scorpion venom that acts similarly to a commonly used chemotherapy drug, employed to kill the cancer cells. Preliminary results of the study showed that the molecule called BamazScplp1, found in the venom of the Brotheas amazonicus scorpion, showed cancer-fighting properties when tested in the lab. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the university and the project's coordinator. Instead of milking the scorpions for venom, the researchers used a process called heterologous expression to produce the required toxin content for the study. In this process, the gene that produces a particular protein is inserted into another organism (often yeast or bacteria) and later produced in large quantities inside the lab. "We also intend to obtain these molecules through heterologous expression," said Ms Arantes, referring to BamazScplp1 and other promising compounds. "Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added. Test results of the peptide on breast cancer cells revealed a response comparable to that of paclitaxel, a chemotherapy drug commonly used to treat the disease. "The peptide induces cell death mainly through necrosis, an action similar to that of molecules identified in other scorpion species," the study highlighted. Breast cancer According to the World Health Organisation (WHO), breast cancer is the most common cancer type in women and the second most common cancer type overall, globally. A study published in Nature Medicine earlier this year revealed that on average, 1 in 20 women worldwide will be diagnosed with breast cancer in their lifetime. If current rates continue, by 2050, there will be 3.2 million new breast cancer cases and 1.1 million breast cancer-related deaths per year. An estimated 2.3 million new breast cancer cases and 670,000 breast cancer-related deaths occurred worldwide in 2022. Most breast cancer cases and deaths occur in individuals aged 50 years and older, who account for 71 per cent of new cases and 79 per cent of deaths.